USD 1.3
(-12.19%)
Year | Total Debt | Total Debt Growth |
---|---|---|
2023 | 85.89 Million USD | 54.07% |
2022 | 55.75 Million USD | 1.37% |
2021 | 54.99 Million USD | 85.06% |
2020 | 29.71 Million USD | 1063.63% |
2019 | 2.55 Million USD | 0.0% |
2018 | - USD | 0.0% |
2017 | - USD | 0.0% |
2016 | - USD | 0.0% |
2015 | - USD | 0.0% |
2014 | - USD | 0.0% |
2013 | - USD | 0.0% |
2012 | - USD | 0.0% |
2011 | - USD | 0.0% |
2010 | - USD | 0.0% |
2009 | - USD | 0.0% |
2008 | - USD | 0.0% |
2007 | - USD | 0.0% |
2006 | - USD | -100.0% |
2005 | 55 Thousand USD | -98.31% |
2004 | 3.24 Million USD | -47.59% |
2003 | 6.19 Million USD | -76.21% |
2002 | 26.02 Million USD | 49.39% |
2001 | 17.41 Million USD | -47.78% |
2000 | 33.35 Million USD | 82.29% |
1999 | 18.3 Million USD | 103.33% |
1998 | 9 Million USD | 291.3% |
1997 | 2.3 Million USD | -17.86% |
1996 | 2.8 Million USD | 0.0% |
Year | Total Debt | Total Debt Growth |
---|---|---|
2024 Q1 | 86.52 Million USD | 0.73% |
2024 Q2 | 87.04 Million USD | 0.59% |
2023 Q1 | 55.84 Million USD | 0.16% |
2023 Q4 | 85.89 Million USD | 53.34% |
2023 Q3 | 56.02 Million USD | 0.16% |
2023 FY | 85.89 Million USD | 54.07% |
2023 Q2 | 55.92 Million USD | 0.15% |
2022 FY | 55.75 Million USD | 1.37% |
2022 Q4 | 55.75 Million USD | 0.45% |
2022 Q1 | 55.21 Million USD | 0.39% |
2022 Q2 | 55.31 Million USD | 0.18% |
2022 Q3 | 55.5 Million USD | 0.35% |
2021 Q4 | 54.99 Million USD | 37.6% |
2021 FY | 54.99 Million USD | 85.06% |
2021 Q1 | 29.77 Million USD | 0.2% |
2021 Q2 | 39.84 Million USD | 33.81% |
2021 Q3 | 39.96 Million USD | 0.31% |
2020 FY | 29.71 Million USD | 1063.63% |
2020 Q4 | 29.71 Million USD | 0.13% |
2020 Q1 | 5.98 Million USD | 134.42% |
2020 Q2 | 5.84 Million USD | -2.34% |
2020 Q3 | 29.67 Million USD | 407.59% |
2019 Q4 | 2.55 Million USD | 631.81% |
2019 FY | 2.55 Million USD | 0.0% |
2019 Q1 | 571 Thousand USD | 0.0% |
2019 Q2 | 402 Thousand USD | -29.6% |
2019 Q3 | 349 Thousand USD | -13.18% |
2018 Q4 | - USD | 0.0% |
2018 FY | - USD | 0.0% |
2018 Q3 | - USD | 0.0% |
2018 Q2 | - USD | 0.0% |
2018 Q1 | - USD | 0.0% |
2017 Q3 | - USD | 0.0% |
2017 Q4 | - USD | 0.0% |
2017 FY | - USD | 0.0% |
2017 Q1 | - USD | 0.0% |
2017 Q2 | - USD | 0.0% |
2016 Q2 | - USD | 0.0% |
2016 Q4 | - USD | 0.0% |
2016 Q1 | - USD | 0.0% |
2016 Q3 | - USD | 0.0% |
2016 FY | - USD | 0.0% |
2015 Q1 | - USD | 0.0% |
2015 Q4 | - USD | 0.0% |
2015 FY | - USD | 0.0% |
2015 Q3 | - USD | 0.0% |
2015 Q2 | - USD | 0.0% |
2014 Q1 | - USD | 0.0% |
2014 FY | - USD | 0.0% |
2014 Q2 | - USD | 0.0% |
2014 Q4 | - USD | 0.0% |
2014 Q3 | - USD | 0.0% |
2013 Q4 | - USD | 0.0% |
2013 Q1 | - USD | 0.0% |
2013 FY | - USD | 0.0% |
2013 Q2 | - USD | 0.0% |
2013 Q3 | - USD | 0.0% |
2012 FY | - USD | 0.0% |
2012 Q4 | - USD | 0.0% |
2012 Q3 | - USD | 0.0% |
2012 Q2 | - USD | 0.0% |
2012 Q1 | - USD | 0.0% |
2011 FY | - USD | 0.0% |
2011 Q1 | - USD | 0.0% |
2011 Q2 | - USD | 0.0% |
2011 Q3 | 3.19 Million USD | 0.0% |
2011 Q4 | - USD | -100.0% |
2010 Q1 | - USD | 0.0% |
2010 FY | - USD | 0.0% |
2010 Q4 | - USD | 0.0% |
2010 Q3 | - USD | 0.0% |
2010 Q2 | - USD | 0.0% |
2009 Q2 | - USD | 0.0% |
2009 FY | - USD | 0.0% |
2009 Q4 | - USD | 0.0% |
2009 Q3 | - USD | 0.0% |
2009 Q1 | - USD | 0.0% |
2008 Q4 | - USD | 0.0% |
2008 FY | - USD | 0.0% |
2008 Q1 | - USD | 0.0% |
2008 Q2 | - USD | 0.0% |
2008 Q3 | - USD | 0.0% |
2007 FY | - USD | 0.0% |
2007 Q4 | - USD | 0.0% |
2007 Q3 | - USD | -100.0% |
2007 Q2 | 877 Thousand USD | 0.0% |
2007 Q1 | - USD | 0.0% |
2006 Q4 | - USD | 0.0% |
2006 Q3 | - USD | 0.0% |
2006 FY | - USD | -100.0% |
2006 Q1 | 28 Thousand USD | -49.09% |
2006 Q2 | - USD | -100.0% |
2005 FY | 55 Thousand USD | -98.31% |
2005 Q4 | 55 Thousand USD | -96.46% |
2005 Q3 | 1.55 Million USD | -13.95% |
2005 Q2 | 1.8 Million USD | -26.38% |
2005 Q1 | 2.45 Million USD | -24.41% |
2004 Q1 | 5.36 Million USD | -13.31% |
2004 Q3 | 4.61 Million USD | -2.29% |
2004 FY | 3.24 Million USD | -47.59% |
2004 Q4 | 3.24 Million USD | -29.61% |
2004 Q2 | 4.71 Million USD | -12.09% |
2003 FY | 6.19 Million USD | -76.21% |
2003 Q1 | 24.77 Million USD | -4.79% |
2003 Q3 | 6.48 Million USD | -12.65% |
2003 Q2 | 7.42 Million USD | -70.04% |
2003 Q4 | 6.19 Million USD | -4.53% |
2002 FY | 26.02 Million USD | 49.39% |
2002 Q1 | 17.2 Million USD | -1.25% |
2002 Q4 | 26.02 Million USD | 54.55% |
2002 Q3 | 16.83 Million USD | -3.73% |
2002 Q2 | 17.49 Million USD | 1.67% |
2001 FY | 17.41 Million USD | -47.78% |
2001 Q2 | 32.94 Million USD | -0.61% |
2001 Q1 | 33.14 Million USD | -0.64% |
2001 Q3 | 37.07 Million USD | 12.53% |
2001 Q4 | 17.41 Million USD | -53.01% |
2000 FY | 33.35 Million USD | 82.29% |
2000 Q3 | 33.62 Million USD | -9.13% |
2000 Q2 | 37 Million USD | 308.57% |
2000 Q1 | 9.05 Million USD | -50.51% |
2000 Q4 | 33.35 Million USD | -0.79% |
1999 Q2 | 12.5 Million USD | 28.87% |
1999 Q1 | 9.7 Million USD | 7.78% |
1999 FY | 18.3 Million USD | 103.33% |
1999 Q4 | 18.3 Million USD | -20.78% |
1999 Q3 | 23.1 Million USD | 84.8% |
1998 Q1 | 2.1 Million USD | -8.7% |
1998 Q2 | 1.9 Million USD | -9.52% |
1998 Q4 | 9 Million USD | 350.0% |
1998 FY | 9 Million USD | 291.3% |
1998 Q3 | 2 Million USD | 5.26% |
1997 Q2 | 2.5 Million USD | -3.85% |
1997 Q1 | 2.6 Million USD | -7.14% |
1997 FY | 2.3 Million USD | -17.86% |
1997 Q4 | 2.3 Million USD | -4.17% |
1997 Q3 | 2.4 Million USD | -4.0% |
1996 Q3 | 2.3 Million USD | -4.17% |
1996 Q4 | 2.8 Million USD | 21.74% |
1996 Q1 | 2.5 Million USD | 0.0% |
1996 FY | 2.8 Million USD | 0.0% |
1996 Q2 | 2.4 Million USD | -4.0% |
Name | Total Debt | Total Debt Difference |
---|---|---|
uniQure N.V. | 138.4 Million USD | 37.938% |
Agios Pharmaceuticals, Inc. | 56.98 Million USD | -50.732% |
Amicus Therapeutics, Inc. | 445.05 Million USD | 80.699% |
Atara Biotherapeutics, Inc. | 57.87 Million USD | -48.429% |
bluebird bio, Inc. | 330.32 Million USD | 73.996% |
Cara Therapeutics, Inc. | 43.16 Million USD | -98.992% |
Imunon, Inc. | 1.13 Million USD | -7439.676% |
Editas Medicine, Inc. | 36.53 Million USD | -135.108% |
IQVIA Holdings Inc. | 14.23 Billion USD | 99.396% |
Mettler-Toledo International Inc. | 2.16 Billion USD | 96.037% |
Myriad Genetics, Inc. | 145 Million USD | 40.759% |
Neurocrine Biosciences, Inc. | 428.4 Million USD | 79.949% |
Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -106.851% |
Verastem, Inc. | 41.55 Million USD | -106.702% |
Walgreens Boots Alliance, Inc. | 9.55 Billion USD | 99.101% |
Waters Corporation | 2.35 Billion USD | 96.353% |
Thermo Fisher Scientific Inc. | 34.91 Billion USD | 99.754% |
Biogen Inc. | 7.33 Billion USD | 98.829% |
Nektar Therapeutics | 230.4 Million USD | 62.718% |
Perrigo Company plc | 4.07 Billion USD | 97.891% |
Dynavax Technologies Corporation | 256.91 Million USD | 66.565% |
Illumina, Inc. | 2.26 Billion USD | 96.203% |
Corbus Pharmaceuticals Holdings, Inc. | 20.88 Million USD | -311.31% |
Iovance Biotherapeutics, Inc. | 1 Million USD | -8489.9% |
Heron Therapeutics, Inc. | 173.75 Million USD | 50.563% |
Unity Biotechnology, Inc. | 26.99 Million USD | -218.262% |
BioMarin Pharmaceutical Inc. | 1.13 Billion USD | 92.424% |
Sangamo Therapeutics, Inc. | 38.1 Million USD | -125.433% |
Evolus, Inc. | 126.54 Million USD | 32.12% |
Adicet Bio, Inc. | 17.7 Million USD | -385.223% |
Aclaris Therapeutics, Inc. | 3.07 Million USD | -2694.372% |
Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 96.822% |
Esperion Therapeutics, Inc. | 540.94 Million USD | 84.121% |
FibroGen, Inc. | 170.45 Million USD | 49.606% |
Agilent Technologies, Inc. | 2.73 Billion USD | 96.859% |
OPKO Health, Inc. | 326.56 Million USD | 73.696% |
Homology Medicines, Inc. | 44.05 Million USD | -94.986% |
Alnylam Pharmaceuticals, Inc. | 2.39 Billion USD | 96.418% |
Exelixis, Inc. | 189.94 Million USD | 54.777% |
Viking Therapeutics, Inc. | 1.26 Million USD | -6717.381% |
Anavex Life Sciences Corp. | - USD | -Infinity% |
Intellia Therapeutics, Inc. | 115.34 Million USD | 25.529% |
Zoetis Inc. | 6.8 Billion USD | 98.737% |
Axsome Therapeutics, Inc. | 186.37 Million USD | 53.91% |
Abeona Therapeutics Inc. | 4.4 Million USD | -1851.363% |
Vertex Pharmaceuticals Incorporated | 808.4 Million USD | 89.374% |
Kala Pharmaceuticals, Inc. | 36.32 Million USD | -136.487% |
Ionis Pharmaceuticals, Inc. | 1.45 Billion USD | 94.09% |
Sarepta Therapeutics, Inc. | 1.39 Billion USD | 93.85% |
Corcept Therapeutics Incorporated | 151 Thousand USD | -56786.755% |
Halozyme Therapeutics, Inc. | 1.49 Billion USD | 94.271% |
Blueprint Medicines Corporation | 774.12 Million USD | 88.904% |
Insmed Incorporated | 1.2 Billion USD | 92.865% |
TG Therapeutics, Inc. | 110.79 Million USD | 22.47% |
Incyte Corporation | 38.28 Million USD | -124.356% |
Emergent BioSolutions Inc. | 877.5 Million USD | 90.211% |